Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics is a radiopharmaceutical company with a lead program targeting somatostatin receptor for neuroendocrine tumors, which is a ~$39B addressable market. The company also has a newly disclosed program targeting CCK2R with up to $6B in additional TAM. With a differentiated vertically integrated approach and upcoming data catalysts, we see Perspective Therapeutics as a leader in the next-gen radiopharmaceutical space and expect the stock to appreciate as data emerges across key pipeline programs.

Bears say

Perspective Therapeutics is facing regulatory discussions and uncertainty regarding their pipeline drugs and upcoming data releases. Their current projected peak sales and market share may not be achievable, especially in a highly competitive market. Additionally, their current valuation is based on lofty revenue and sales projections, which may be overly optimistic and not realistic in the long term. Furthermore, the company's recent financial data shows a net loss of $9 million and a decrease in cash and cash equivalents by $93 million, signaling potential financial struggles in the future.

CATX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Buy based on their latest research and market trends.

According to 10 analysts, CATX has a Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.